Non-Alcoholic Fatty Liver Disease in Proceedings of Congress Easl – 2023

Abstract

Background. The significant increase in the prevalence of type 2 diabetes has led to an increase in the incidence of its hepatic manifestations, in particular non-alcoholic fatty liver disease. A complication of this disease is the asymptomatic progression of fibrosis, the development of liver cirrhosis and hepatocellular carcinoma.
 Aim. To analyze the results of studies on non-alcoholic fatty liver disease that were reviewed at the Congress of the European Association for the Study of the Liver (EASL - 2023).
 Materials and methods. Analysis of current data presented in the materials of the Congress of the European Association for the Study of the Liver (EASL - 2023) on the prevalence, pathogenesis and treatment of non-alcoholic fatty liver disease.
 Conclution. Non-alcoholic fatty liver disease and the new term metabolic associated steatohepatitis (MASH) are the hepatic manifestations of type 2 diabetes mellitus, the prevalence of which is rapidly increasing with the increasing incidence of uncontrolled hyperglycemia. The new term MASH, which replaced the diagnosis of NAFLD, emphasizes that the main etiopathogenetic factor in the development of this liver pathology is type 2 diabetes mellitus. The progression of liver fibrosis and the development of hepatocellular carcinoma in MASH can be caused not only by a high level of glycated hemoglobin, but also by multiple comorbid factors, in particular, autoimmune hepatitis, alcoholic and drug-induced liver damage, hemochromatosis, etc.